GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Actavia Life Sciences Inc (OTCPK:RASP) » Definitions » Shiller PE Ratio

Actavia Life Sciences (Actavia Life Sciences) Shiller PE Ratio : (As of Jun. 10, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Actavia Life Sciences Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Actavia Life Sciences Shiller PE Ratio Historical Data

The historical data trend for Actavia Life Sciences's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Actavia Life Sciences Shiller PE Ratio Chart

Actavia Life Sciences Annual Data
Trend Jun14 Jun15 Jun16 Mar17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Actavia Life Sciences Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Actavia Life Sciences's Shiller PE Ratio

For the Biotechnology subindustry, Actavia Life Sciences's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Actavia Life Sciences's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Actavia Life Sciences's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Actavia Life Sciences's Shiller PE Ratio falls into.



Actavia Life Sciences Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Actavia Life Sciences's E10 for the quarter that ended in Mar. 2024 is calculated as:

For example, Actavia Life Sciences's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0/131.7762*131.7762
=0.000

Current CPI (Mar. 2024) = 131.7762.

Actavia Life Sciences Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201406 -0.001 100.560 -0.001
201409 0.000 100.428 0.000
201412 0.000 99.070 0.000
201503 -0.001 99.621 -0.001
201506 -0.002 100.684 -0.003
201509 0.000 100.392 0.000
201512 0.000 99.792 0.000
201603 0.000 100.470 0.000
201606 -0.006 101.688 -0.008
201609 -0.020 101.861 -0.026
201612 -0.020 101.863 -0.026
201703 -0.010 102.862 -0.013
201706 -0.020 103.349 -0.026
201709 -0.020 104.136 -0.025
201712 -0.030 104.011 -0.038
201803 -0.020 105.290 -0.025
201806 -0.010 106.317 -0.012
201809 -0.010 106.507 -0.012
201812 -0.010 105.998 -0.012
201903 -0.004 107.251 -0.005
201906 -0.003 108.070 -0.004
201909 0.000 108.329 0.000
201912 -0.002 108.420 -0.002
202003 -0.003 108.902 -0.004
202006 -0.040 108.767 -0.048
202009 -0.040 109.815 -0.048
202012 -0.002 109.897 -0.002
202103 -0.004 111.754 -0.005
202106 -0.002 114.631 -0.002
202109 0.000 115.734 0.000
202112 -0.004 117.630 -0.004
202203 0.002 121.301 0.002
202206 -0.005 125.017 -0.005
202209 0.000 125.227 0.000
202212 -0.001 125.222 -0.001
202303 -0.007 127.348 -0.007
202306 0.000 128.729 0.000
202309 -0.001 129.860 -0.001
202312 0.000 129.419 0.000
202403 0.000 131.776 0.000

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Actavia Life Sciences  (OTCPK:RASP) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Actavia Life Sciences Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Actavia Life Sciences's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Actavia Life Sciences (Actavia Life Sciences) Business Description

Traded in Other Exchanges
N/A
Address
420 Lexington Avenue, Suite 2525, New York, NY, USA, 10170
Rasna Therapeutics Inc is a clinical-stage biotechnology company focused on targeted drugs to treat diseases in oncology and immunology, mainly focusing on the treatment of leukemia. Its primary indication is Acute Myeloid Leukemia (AML), which may be fatal within weeks to months, has about a 5-year survival rate of only about 25% and very poor prospects for the long-term survival of patients.

Actavia Life Sciences (Actavia Life Sciences) Headlines

No Headlines